Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2013

01-06-2013 | Research Article

Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer

Authors: T. Gui, Y. Wang, Y. Mao, J. Liu, S. Sun, D. Cao, J. Yang, K. Shen

Published in: Clinical and Translational Oncology | Issue 6/2013

Login to get access

Abstract

Objective

To compare the differences between 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) with traditional after-loading radiotherapy in aspects of efficacies and side effects.

Materials and methods

MTT assay was adopted to detect the inhibitive effects of 5-ALA-PDT on Hela cells proliferation. Flow cytometry was used to analyze cell apoptosis. After establishment of human cervical cancer xenograft model, the comparisons between 5-ALA-PDT with radiotherapy were performed with respect to treatment efficacies (survival rate, body weight, and tumor volume) and side effects (appearance and behavior, ovarian endocrine functions, and skin lesion around the tumor).

Results

5-Aminolevulinic acid photodynamic therapy exerted killing effects on cervical cancer cells. Morphological changes and flow cytometric analyses indicated apoptosis to be one of the mechanisms for tumor growth suppression. Both proliferation inhibition and cell apoptosis showed dependency on photosensitizer concentration and irradiation intensity. Repeated photodynamic therapy presented stronger inhibitive effects on tumor growth compared to after-loading radiotherapy, while producing milder impairment of ovarian endocrine functions and skin lesions around the tumors.

Conclusions

5-Aminolevulinic acid photodynamic therapy has great potential to be an alternative treatment modality for cervical cancer.
Literature
1.
Torres LA, Rojo HG, Torres RA, Hurtado Estrada G, Roman Bassaure E (2004) Cervical cancer: current view of its epidemiology and risk factors. Ginecol Obstet Mex 72:466–474
2.
Wells SF (2008) Cervical cancer: an overview with suggested practice and policy goals. Medsurg Nurs 17(1):43–50PubMed
3.
Macchia G, Ferrandina G, Deodato F, Bibbo R, Massaccesi M, Ippolito E et al (2011) 3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I–II study (ADA-RT-1). Gynecol Oncol 120(3):485–488PubMedCrossRef
4.
Robova H, Halaska M, Pluta M, Skapa P, Strnad P, Lisy J et al (2010) The role of neoadjuvant chemotherapy and surgery in cervical cancer. Int J Gynecol Cancer 20(11 Suppl 2):S42–S46PubMedCrossRef
5.
Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, Gonzalez S (2008) Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 10(3):148–154PubMedCrossRef
6.
Perotti C, Casas A, Fukuda H, Sacca P, Batlle A (2003) Topical application of ALA and ALA hexyl ester on a subcutaneous murine mammary adenocarcinoma: tissue distribution. Br J Cancer 88(3):432–437PubMedCrossRef
7.
Tunstall RG, Barnett AA, Schofield J, Griffiths J, Vernon DI, Brown SB et al (2002) Porphyrin accumulation induced by 5-aminolevilunic acid esters in tumor cells growing in vitro and in vivo. Br J Cancer 87(2):246–250PubMedCrossRef
8.
Zhu TC, Finlay JC (2008) The role of photodynamic therapy (PDT) physics. Med Phys 35(7):3127–3136PubMedCrossRef
9.
Lehmann P (2007) Methyl aminolaevulinate–photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 156(5):793–801PubMedCrossRef
10.
Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A (1978) Photoradiation therapy for the treatment of malignant tumors. Cancer Res 38(8):2628–2635PubMed
11.
He GF, Bian ML, Zhao YW, Xiang Q, Li HY, Xiao C (2009) A study on the mechanism of 5-aminolevulinic acid photodynamic therapy in vitro and in vivo in cervical cancer. Oncol Rep 21(4):861–868PubMed
12.
Kim WC, Kim GE, Suh CO, Loh JJ (2001) High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix. Jpn J Clin Oncol 31(9):432–437PubMedCrossRef
13.
Shakespeare TP, Lim KH, Lee KM, Back MF, Mukherjee R, Lu JD, American Brachytherapy Society (2006) Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45–50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable? Int J Gynecol Cancer 16(1):277–282PubMedCrossRef
14.
Kwon OC, Yoon HJ, Kim KH, Kim HT, Yoon YH, Kim JK (2008) Fluorescence kinetics of protoporphyrin-IX induced from 5-ALA compounds in rabbit postballoon injury model for ALA-photoangioplasty. Photochem Photobiol 84(5):1209–1214PubMedCrossRef
15.
af Klinteberg C, af Klinteberg C, Enejder AM, Wang I, Andersson-Engels S, Svanberg S, Svanberg K (1999) Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas. J Photochem Photobiol B 49(2–3):120–128PubMedCrossRef
16.
Heil P, Stocker S, Sroka R, Baumgartner R (1997) In vivo fluorescence kinetics of porphyrins following intravesical instillation of 5-aminolaevulinic acid in normal and tumor-bearing rat bladders. J Photochem Photobiol B 38(2–3):158–163PubMedCrossRef
17.
Juzenas P, Sharfaei S, Moan J, Bissonnette R (2002) Protoporphyrin IX fluorescence kinetics in UV-induced tumors and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester. J Photochem Photobiol B 67(1):11–17PubMedCrossRef
18.
Johansen P, Berg K, Selbo PK, Hofbauer GF (2010) Photochemical internalization (PCI): a further development of photodynamic therapy for the treatment of skin cancer. Praxis (Bern 1994) 99(23):1423–1428CrossRef
19.
Swartling J, Axelsson J, Ahlgren G, Kalkner KM, Nilsson S, Svanberg S et al (2010) System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer. J Biomed Opt 15(5):058003PubMedCrossRef
20.
Johansson A, Palte G, Schnell O, Tonn JC, Herms J, Stepp H (2010) 5-Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 86(6):1373–1378PubMedCrossRef
21.
Gross SA, Wolfsen HC (2010) The role of photodynamic therapy in the esophagus. Gastrointest Endosc Clin N Am 20:35–53PubMedCrossRef
22.
Grant WE, Speight PM, Hopper C, Bown SG (1997) Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int J Cancer 71(6):937–942PubMedCrossRef
23.
Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D et al (2004) Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 22(11):2192–2201PubMedCrossRef
24.
Chiaviello A, Paciello I, Postiglione I, Crescenzi E, Palumbo G (2010) Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis. Cell Prolif 43(5):480–493PubMedCrossRef
25.
Zhao B, He YY (2010) Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther 10(11):1797–1809PubMedCrossRef
26.
Mackenzie GD, Dunn JM, Selvasekar CR, Mosse CA, Thorpe SM, Novelli MR et al (2009) Optimal conditions for successful ablation of high-grade dysplasia in Barrett’s oesophagus using aminolevulinic acid photodynamic therapy. Lasers Med Sci 24(5):729–734PubMedCrossRef
Metadata
Title
Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer
Authors
T. Gui
Y. Wang
Y. Mao
J. Liu
S. Sun
D. Cao
J. Yang
K. Shen
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0945-5

Other articles of this Issue 6/2013

Clinical and Translational Oncology 6/2013 Go to the issue

Research Article

A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display

Erratum

Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Research Article

Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases

Research Article

Is it necessary to dissect the lymph nodes around an abnormal hepatic artery in D2 lymphadenectomy for gastric cancer?

Research Article

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey

Research Article

Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits